Breaking Finance News

T2 Biosystems Inc (NASDAQ:TTOO) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $6.50, T2 Biosystems Inc (NASDAQ:TTOO) traded 5.90% higher on the day. With the last stock price down -0.40% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. TTOO has recorded a 50-day average of $6.89 and a two hundred day average of $7.93. Trade Volume was up over the average, with 352,907 shares of TTOO changing hands over the typical 184,439

Zacks Investment Research has upgraded T2 Biosystems Inc (NASDAQ:TTOO) to Hold in a statement released on 9/22/2016.

Recent Performance Chart

T2 Biosystems Inc (NASDAQ:TTOO)

T2 Biosystems Inc has with a one year low of $4.92 and a one year high of $12.30 and has a market capitalization of $0.

A total of 7 firms have issued a report on the stock. 3 firms rating the stock a strong buy, two equity analysts rating the company a buy, three equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $12.71.

Brief Synopsis About T2 Biosystems Inc (NASDAQ:TTOO)

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *